InvestorsObserver
Sign Up Login

MRNA Moderna Inc

$182.35 $0.00 (0.00%)
Add to Watchlist Compare
Overall

MRNA Stock Analysis Overview

What this means: Moderna Inc (MRNA) gets an Overall Rank of 61, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. MRNA's 61 means that it ranks higher than 61% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

MRNA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

MRNA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

MRNA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

MRNA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

MRNA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

MRNA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

MRNA Stock Analysis Overview

What this means: Moderna Inc (MRNA) gets an Overall Rank of 61, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. MRNA's 61 means that it ranks higher than 61% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full MRNA report

MRNA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

MRNA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

MRNA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

MRNA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

MRNA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

MRNA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Moderna Inc (MRNA) Analyst Forecast

MRNA Price, Volume, Earnings, and Dividend Date

  • Last Price $182.35
  • Previous Close $182.35
  • Change $0.00
  • Open $178.50
  • Volume 2,761,519
  • Avg. Volume (100-day) 4,654,949
  • Market Cap 70,055,308,522
  • Days Range 177 - 182.8
  • 52-week Range 115.03 - 321.3
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E 3.3
  • EPS 55.28
  • Earnings Date 02/01/23
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.614
  • PEG Ratio 1.26

Moderna Inc (MRNA) Company Description

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna Inc (MRNA) Stock Chart

View Interactive MRNA chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Oncolytics Biotech Inc (ONCY) (ONCY) $1.85
Glycomimetics Inc (GLYC) (GLYC) $2.29
SC Pharmaceuticals Inc (SCPH) (SCPH) $7.05
Vectivbio Holding Ag (VECT) (VECT) $8.22
Oyster Point Pharma Inc (OYST) (OYST) $11.12
Actinium Pharmaceuticals Inc (ATNM) (ATNM) $11.27
Lava Therapeutics N.V. (LVTX) (LVTX) $7.31
Mersana Therapeutics Inc (MRSN) (MRSN) $7.25
Viking Thera (VKTX) (VKTX) $4.26
Biocardia Inc (BCDA) (BCDA) $1.79